Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

被引：0
|
作者：
Hara Kousoulakou
Magdalini Hatzikou
Varvara Baroutsou
John Yfantopoulos
机构：
[1] University of Peloponnese,
[2] Novartis Hellas SACI,undefined
[3] National and Kapodistrian University of Athens,undefined
[4] School of Economics and Political Science ,undefined
来源：
Cost Effectiveness and Resource Allocation | / 15卷
关键词：
Vildagliptin; Type 2 diabetes mellitus; Cost-effectiveness; Greece;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Jason Gordon
    Phil McEwan
    Michael Hurst
    Jorge Puelles
    Diabetes Therapy, 2016, 7 : 825 - 845
  • [22] Cost-effectiveness of metformin plus vildagliptin versus metformin plus sulphonylurea for the treatment of type 2 diabetes patients in Portugal
    Viriato, D.
    Calado, F.
    Gruenberger, J-B.
    Ong, S. H.
    Carvalho, D.
    Silva-Nunes, J.
    Johal, S.
    Viana, R.
    DIABETOLOGIA, 2014, 57 : S328 - S328
  • [23] Vildagliptin versus insulin as add-on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled trial
    Strotmann, H. -J.
    Goetze, D.
    Koch, C.
    Forst, T.
    DIABETOLOGIA, 2014, 57 : S364 - S365
  • [24] Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting
    Melzer Cohen, Cheli
    Davis, Carla
    Shalev, Varda
    Chodick, Gabriel
    JOURNAL OF DIABETES, 2018, 10 (01) : 68 - 72
  • [25] Better adherence with vildagliptin add-on to metformin than sulphonylurea add-on to metformin among Muslim patients with type 2 diabetes mellitus fasting during Ramadan
    Hanif, W.
    Malik, W.
    Hassanein, M.
    Kamal, A.
    Geransar, P.
    Lister, N.
    Andrews, C.
    Barnett, A. H.
    DIABETOLOGIA, 2011, 54 : S342 - S342
  • [26] Empaglilozin compared with glimepiride as add-on to metformin for 2 years in patients with type 2 diabetes
    Ridderstrale, M.
    Andersen, K. R.
    Zeller, C.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S7 - S8
  • [27] COMPARATIVE EFFECTIVENESS OF TENELIGLIPTIN VERSUS GLIMEPIRIDE AS ADD ON MEDICATIONS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN
    Atal, S.
    Joshi, R.
    Fatima, Z.
    Balakrishnan, S.
    Das, S.
    Vaidya, S.
    VALUE IN HEALTH, 2022, 25 (12) : S28 - S28
  • [28] Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus
    Jawed, Bilal
    Ahmed, Shadab
    Abbas, Syed Qamar
    Ahmed, Zeeshan
    Andleeb, Shomaiza
    Ahmad, Salman Ashfaq
    Asif, Muhammad
    Akhter, Erum
    Ahmed, Salman
    Hussain, Muhammad Waleed
    Iqbal, Adnan
    Ishaqui, Azfar Athar
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (06) : 1733 - 1738
  • [29] COST-EFFECTIVENESS OF ADD-ON THERAPIES TO METFORMIN: THE IMPACT OF MEDICATION ADHERENCE FOR TYPE 2 DIABETES MELLITUS
    Ho, C. M.
    Yeh, T. H.
    Lai, Y. T.
    VALUE IN HEALTH, 2021, 24 : S80 - S80
  • [30] Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
    Mueller-Wieland, Dirk
    Kellerer, Monika
    Cypryk, Katarzyna
    Skripova, Dasa
    Rohwedder, Katja
    Johnsson, Eva
    Garcia-Sanchez, Ricardo
    Kurlyandskaya, Raisa
    Sjostrom, C. David
    Jacob, Stephan
    Seufert, Jochen
    Dronamraju, Nalina
    Csomos, Katalin
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2598 - 2607
12345